<DOC>
	<DOCNO>NCT01435616</DOCNO>
	<brief_summary>The purpose study : - To compare blood sugar control LY2605541 insulin glargine 52 week treatment . - To compare number night time low blood sugar episode LY2605541 insulin glargine 52 week treatment . - To compare number patient LY2605541 reach blood sugar target without low blood sugar episode night take insulin glargine 52 week treatment . - To compare total number low blood sugar episode LY2605541 insulin glargine 52 week treatment</brief_summary>
	<brief_title>A Study Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have type 2 diabetes mellitus , treat insulin , least one year prior study Have receive least 2 oral antihyperglycemic medication least 3 month enter study Have hemoglobin A1c value 7.0 % 11.0 % , inclusive , screen Are capable , willing inject insulin vial syringe perform self blood glucose monitoring Woman Childbearing potential : breastfeeding , negative pregnancy test time screen randomization intend become pregnant trial . Have practice reliable method birth control least 6 week prior screen agree use reliable method birth control study 2 week follow last dose study drug Have use insulin therapy ( outside pregnancy ) anytime past 2 year , except shortterm treatment acute condition , maximum 4 continuous week Use rosiglitazone , pramlintide , glucagonlike peptide 1 ( GLP1 ) receptor agonist ( example , exenatide , exenatide weekly , liraglutide ) concurrently within 3 month prior screen Are currently take , take within 3 month precede screening , medication promote weight loss Have episode severe hypoglycemia within 6 month prior screen Have 1 episode ketoacidosis hyperosmolar state/coma 6 month prior study Have cardiac disease functional status New York Heart Association Class III IV ( per New York Heart Association [ NYHA ] Cardiac Disease Classification ) Have history renal transplantation , currently receive renal dialysis serum creatinine great equal 2 mg/dL Have obvious clinical sign symptom liver disease ( exclude non alcoholic fatty liver disease [ NAFLD ] ) , acute chronic hepatitis , nonalcoholic steatohepatitis ( NASH ) , elevate liver enzyme measurement screen Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia sickle cell anemia , traits hemoglobin abnormality know interfere measurement hemoglobin A1c Have active untreated malignancy , remission clinically significant malignancy le 5 year Have fast nonfasting triglyceride great 400 mg/dL ( great 4.5 mmol/L ) screening Are use lipid lower medication dose stable 90 day prior screen Are use niacin preparation lipid lower medication bile acid sequestrants within 90 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>insulin naive</keyword>
	<keyword>insulin treatment</keyword>
</DOC>